Nitric oxide release from human corpus cavernosum induced by a purified scorpion toxin

Urology

Volumn 63, Issue 1, 2004, Pages 184-189

  Teixeira, Cleber E ^a   De Oliveira, Juliano F ^a   Baracat, Juliana S ^a   Priviero, Fernanda B M ^a   Okuyama, Cristina E ^a   Rodrigues Netto Jr , Nelson ^a   Fregonesi, Adriano ^a   Antunes, Edson ^a   De Nucci, Gilberto ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1H [1,2,4]OXADIAZOLO(4,3 ALQUINOXALIN 1 ONE); GUANYLATE CYCLASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PHOSPHODIESTERASE V; SCORPION VENOM; SILDENAFIL; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CORPUS CAVERNOSUM; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MUSCLE RELAXATION; MUSCLE TISSUE; NITRERGIC NERVE; PRIAPISM; PRIORITY JOURNAL; SCHOOL CHILD; SODIUM TRANSPORT; STIMULUS RESPONSE;

EID: 0742306929     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00785-4     Document Type: Article

References (30)

1. Bivalacqua T.J., Champion H.C., Hellstrom W.J., et al. Pharmacotherapy for erectile dysfunction. Trends Pharmacol Sci. 21:2000;484-489.
2. Lue T.F. Erectile dysfunction. N Engl J Med. 342:2000;1802-1813.
3. Berger R., Billups K., Brock G. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res. 13:(suppl 5):2001;S39-S43.
4. Keoghane S.R., Sullivan M.E., Miller M.A. The aetiology, pathogenesis and management of priapism. BJU Int. 90:2002;149-154.
5. Bawaskar H.S. Diagnostic cardiac premonitory signs and symptoms of red scorpion sting. Lancet. 1:1982;552-554.
6. Amitai Y., Mines Y., Aker M., et al. Scorpion sting in children a review of 51 cases . Clin Pediatr. 24:1985;136-140.
7. Hershkovich Y., Elitsur Y., Margolis C.Z., et al. Criteria map audit of scorpion envenomation in Negev, Israel. Toxicon. 23:1985;845-854.
8. Freire-Maia L., Campos J.A. Pathophysiology and treatment of scorpion poisoning. Ownby C.L., Odell G.V. Natural Toxins - Characterization, Pharmacology and Therapeutics. 1989;139-159 Pergamon Press, Oxford.
9. Freire-Maia L., Campos J.A., Amaral C.F. Approaches to the treatment of scorpion envenoming. Toxicon. 32:1994;1009-1014.
10. Teixeira C.E., Bento A.C., Lopes-Martins R.A.B., et al. Tityus serrulatus scorpion venom relaxes the isolated rabbit corpus cavernosum by activating NANC nitrergic nerve fibers. Br J Pharmacol. 123:1998;435-442.
11. Teixeira C.E., Faro R., Moreno R.A., et al. Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom. Urology. 57:2001;816-820.
12. Teixeira C.E., Ifa D.R., Corso G., et al. Sequence and structure-activity relationship of a scorpion venom toxin with nitrergic activity in rabbit corpus cavernosum. FASEB J. 17:2003;485-487.
13. Furchgott R.F. Studies on relaxation of rabbit aorta by sodium nitrite the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide . Vanhoutte P.M. Vasodilatation. 1988;401-414 Raven Press, New York.
14. Andersson K.E. Pharmacology of penile erection. Pharmacol Rev. 53:2001;417-450.
15. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 52:2000;375-414.
16. Brioni J.D., Nakane M., Hsieh G.C., et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 14:2002;8-14.
17. Mizusawa H., Hedlund P., Brioni J.D., et al. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol. 167:2002;2276-2281.
18. Nakane M., Hsieh G., Miller L.N., et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue synergism of nitric oxide and YC-1 . Int J Impot Res. 14:2002;121-127.
19. Kalsi J.S., Rees R.W., Hobbs A.J., et al. BAY 41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol. 169:2003;761-766.
20. Kuthe A., Wiedenroth A., Magert H.J., et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol. 165:2001;280-283.
21. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
22. Cestele S., Catterall W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie. 82:2000;883-892.
23. Ignarro L.J., Bush P.A., Buga G.M., et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun. 170:1990;843-850.
24. Leone A.M., Wiklund N.P., Hokfelt T., et al. Release of nitric oxide by nerve stimulation in the human urogenital tract. Neuroreport. 24:1994;733-736.
25. Okamura T., Ayajiki K., Toda N. Monkey corpus cavernosum relaxation mediated by NO and other relaxing factor derived from nerves. Am J Physiol. 274:1998;H1075-H1081.
26. Recio P., Lopez P.G., Hernandez M., et al. Nitrergic relaxation of the horse corpus cavernosum role of cGMP . Eur J Pharmacol. 351:1998;85-94.
27. Hedlund P., Alm P., Andersson K.E. NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol. 127:1999;349-360.
28. Mizusawa H., Hedlund P., Hakansson A., et al. Morphological and functional in vitro and in vivo characterization of the mouse corpus cavernosum. Br J Pharmacol. 132:2001;1333-1341.
29. Teixeira C.E., Teixeira S.A., Antunes E., et al. The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms. Toxicon. 39:2001;633-639.
30. Fernandes-de-Oliveira J, Teixeira CE, Arantes EC, et al: The relaxation of rabbit corpus cavernosum by selective activators of sodium channels: role of the nitric oxide-cyclic GMP pathway. Urology 62: 581-588, 2003.